BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Metabolism of nitric oxide
,
Quercetin
,
rs3825942
,
EGFR
,
calcium channel activity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
mk2206
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
XIST
WIF1
CRIP1
SERPINA3
MAL
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
regulation of nitrogen compound metabolic process
organic cyclic compound binding
cytosol
heterocyclic compound binding
organic cyclic compound metabolic process
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Non-small cell lung cancer NCI-H1666 cells infected with Influenza A(H1N1) and treated with MK2206
Breast cancer cell lines and xenografts treated with PI3KA or AKT inhibitors
Osteosarcoma U-2 OS cells treated with 6 different small molecules
Prostate cancer mouse models treated with different compounds
Breast duct carcinoma T-47D cells treated with AKT inhibitor MK2206
Explore Curated Studies Results
Literature
Most Relevant Literature
MK2206 attenuates atherosclerosis by inhibiting lipid accumulation, cell migration, proliferation, a…
The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calr…
Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via ap…
Co-Administration of Anticancer Candidate MK-2206 Enhances the Efficacy of BCG Vaccine Against Mycob…
Central and peripheral emetic loci contribute to vomiting evoked by the Akt inhibitor MK-2206 in the…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ